---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-031389"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-09-28T21:07:31+00:00"
generated_at: "2026-10-12T13:38:01.347560+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CervoMed says new 50 mg neflamapimod tablet plus FDA removal of exposure limit enables 100 mg BID dosing

## Summary
- New 50 mg tablet uses most stable crystalline form, addressing manufacturing variability of the 40 mg capsule in Phase 2b RewinD-LB; Phase 1 food-effect/drug-exposure study met primary objectives.
- 50 mg tablet vs prior 40 mg capsule: similar overall plasma exposure, ~20% lower Cmax and ~20% higher 12-hour trough, supporting twice-daily dosing.
- FDA removed neflamapimod's prior plasma exposure limit after a 39-week dog tox study set a NOAEL 3-fold higher than prior dog studies and >30x the active clinical exposure range.
- Plans 100 mg BID regimen; PK modeling projects ~33% higher trough levels than the 40 mg TID dose used in Phase 2a and the Phase 2b extension in DLB, cutting dosing to twice daily.
- CEO John J. Alam says the new tablet addresses the formulation issue from RewinD-LB and expects substantially higher trough concentrations, reducing clinical execution and CMC risk.

## SEC filing metadata
- accession: 0001437749-26-031389
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-09-28T21:07:31+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926031389/0001437749-26-031389-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926031389/crvo20260928_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-031389
- JSON: https://secwatch.observer/filing/0001437749-26-031389.json
- Plain text: https://secwatch.observer/filing/0001437749-26-031389.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.